Nowadays, we are all eager to practice evidence-based medicine, and of course agree that the randomized controlled clinical trial (RCT) or a meta-analysis of them, is the gold standard in terms of clinical evidence. Unfortunately, doing RCTs is often not easy-it can be very difficult to fund, take years to publication, and may be difficult to recruit in order to make their results generalizable. To make sure we do the right RCTs, it is important that clinical practice should inform us which trials are needed and ensure they pose the clinical questions that are the most relevant. Some of these key clinically relevant questions may be difficult to study in the context of an RCT, and as a result, the ''easy to do'' trials are not always the ones that are the most needed. Even in the absence of relevant trials, clinical decisions still need to be made-both by clinicians and by the patients-and we must be aware that flawed decisions may result if relevant RCTs do not exist.
Abdominal aortic aneurysm (AAA) repair is a procedure that has been carried out for more than 60 years since the first successful case operated by Du Bost in 1952. 1 We now have substantial experience and outcome evidence concerning AAA repair but relatively few high-quality clinical trials. Current areas of interest concern the role of screening for AAAs, the size at which they should be repaired, and the role of medical therapy and the balance between traditional open surgical techniques and more minimally invasive endovascular aneurysm repair (EVAR) techniques. 2 It is the last which has formed the basis for an interesting study published in this issue by Firwana and colleagues ''Open Repair Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms: Do We Need More Randomized Clinical Trials?'' in which they used the statistical technique of trial sequential analysis (TSA). 3 Their conclusions are that for short-term mortality, we do not need more RCTs to detect the effectiveness of EVAR versus open repair. For longterm mortality, further RCTs were recommended to study longterm mortality and need for reintervention.
We are somewhat uneasy about determining the need for RCTs based on TSA alone. When a clinician is considering the choice between endovascular repair and open AAA surgery, the RCT data are important not just for decision making but also to inform the discussion with patients around consent. The tradeoffs between longer and shorter term results and the advantages of a less invasive procedure may be perceived differently by individuals. Clinical decision making is about single, individual decisions and the conclusion of Firwana and colleagues 3 that there would be no extra benefit in conducting more RCTs to detect effectiveness of EVAR versus open repair may be correct when considering ''group'' data but does not reflect the situation for individuals who may have higher or lower risks and different individual preferences about how those risks should be balanced. In any event, progress is constant in AAA surgery as in most fields-as soon as another trial is published, it can provide a different perspective and new valid questions constantly arise. Additionally, the technology for EVAR is being refined almost weekly as the failings of previous generations of AAA stents are improved upon by manufacturers. This may mean that previous studies are not providing accurate estimates of ''need for reintervention'' for example. Additionally, risk stratification using newer techniques such as cardiopulmonary exercise testing my allow identification of higher risk patients for open surgery.
Our observation from clinical practice is that most patients offered a less-invasive technique will take it up in preference to open surgery if they are presented as roughly equivalent alternatives. The difficult patient group is those that have a high risk for open surgery but are not ideally suited for endovascular repair. Should these be offered a suboptimal endovascular solution or managed conservatively? And how do we balance their aneurysm risk, their anesthetic risk, and their risk of dying from other cardiovascular disorders such as myocardial infarction? We agree with Firwana et al 3 that ''the reason for conducting more RCTs should be to further examine the long-term all-cause mortality and quality of life'' but suggest they are best guided by unresolved relevant clinical questions and not TSA alone.
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